Berg Anne T, Mahida Sonal, Poduri Annapurna
Division of Neurology, Epilepsy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
Ann Clin Transl Neurol. 2021 Mar;8(3):666-676. doi: 10.1002/acn3.51316. Epub 2021 Feb 22.
KCNQ2-associated developmental and epileptic encephalopathies (DEE) present with seizures and developmental impairments. The relation between seizures and functional impairments in affected children and the relation of a specific genetic variant to seizure control remains unknown.
Parents of children with documented KCNQ2 variants who participated in a structured, online natural history survey provided information about seizure history, functional mobility, hand use, communication function, and feeding independence. Bivariate analyses were performed with nonparametric methods and logistic regression was used for multivariable analyses.
Thirty-nine children (20, 51% girls, median age 4.5 years, interquartile range (IQR) 1.9-19.3) had a median age of seizure onset of 1 day (IQR 1-3 days). The most common seizure types were bilateral tonic-clonic (N = 72, 28%) and bilateral tonic (N = 13, 33%). Time since last seizure was <6 months (N = 18, 46%), 6-23 months (N = 11, 28%), and ≥24 months (N = 10 26%). Severe functional impairment was reported for mobility (62%), hand grasp (31%), feeding (59%), and communication (77%). Twenty-eight (72%) were impaired in ≥2 domains. There were only weak and inconsistent associations between seizure recency and individual impairments or number of impairments after adjustment for other factors. The functional location of the variants within the K 7.2 protein was not associated with seizure control.
Seizures in KCNQ2-DEE are often well-controlled, but children have severe impairments regardless. With the increased potential for precision therapies targeting the K 7.2 channel or the KCNQ2 gene itself, identifying the most relevant and sensitive clinical endpoints will be critical to ensure successful trials of new therapies.
与KCNQ2相关的发育性和癫痫性脑病(DEE)表现为癫痫发作和发育障碍。受影响儿童癫痫发作与功能障碍之间的关系以及特定基因变异与癫痫控制之间的关系尚不清楚。
参与结构化在线自然病史调查的有记录KCNQ2变异儿童的父母提供了癫痫发作史、功能活动能力、手部使用、沟通功能和进食独立性等信息。采用非参数方法进行双变量分析,并使用逻辑回归进行多变量分析。
39名儿童(20名,51%为女孩,中位年龄4.5岁,四分位间距(IQR)1.9 - 19.3)癫痫发作的中位起病年龄为1天(IQR 1 - 3天)。最常见的癫痫发作类型是双侧强直阵挛发作(N = 72,28%)和双侧强直发作(N = 13,33%)。距上次癫痫发作的时间<6个月(N = 18,46%)、6 - 23个月(N = 11,28%)和≥24个月(N = 10,26%)。报告显示在活动能力(62%)、手部抓握(31%)、进食(59%)和沟通(77%)方面存在严重功能障碍。28名(72%)在≥2个领域存在功能受损。在调整其他因素后,癫痫发作近期情况与个体功能障碍或功能障碍数量之间仅存在微弱且不一致的关联。K7.2蛋白内变异的功能位置与癫痫控制无关。
KCNQ2 - DEE中的癫痫发作通常得到良好控制,但儿童无论如何都存在严重功能障碍。随着针对K7.2通道或KCNQ2基因本身的精准治疗潜力增加,确定最相关和敏感的临床终点对于确保新疗法的成功试验至关重要。